Advertisement
Journal of Hepatology
EASL
Advanced searchSave search
Letter to the Editor| Volume 77, ISSUE 6, P1728-1729, December 2022

An individualized cirrhosis screening strategy might be more cost-effective in the general population

  • Siru Zhao
    Affiliations
    State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China
    Search for articles by this author
  • Xingmei Liao
    Affiliations
    State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China
    Search for articles by this author
  • Rong Fan
    Correspondence
    Corresponding author. Address: Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. Tel.: 020-62787432, fax: 020-62786534.
    Affiliations
    State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China
    Search for articles by this author
Published:July 14, 2022DOI:https://doi.org/10.1016/j.jhep.2022.06.035
An individualized cirrhosis screening strategy might be more cost-effective in the general population
Previous ArticleReply to: “Challenges and issues in bivariate endpoints in study designs of translational medicine”
Next ArticleReply to: “An individualized cirrhosis screening strategy might be more cost-effective in the general population”
      We read with great interest the article by Labenz, Arslanow et al.
      • Labenz C.
      • Arslanow A.
      • Nguyen-Tat M.
      • Nagel M.
      • Worns M.A.
      • Reichert M.C.
      • et al.
      Structured early detection of asymptomatic liver cirrhosis: results of the population-based liver screening program SEAL.
      J Hepatol. 2022; (S0168-8278(22)00244-00246. https://dx.doi.org/10.1016/j.jhep.2022.04.009)
      recently published in Journal of Hepatology. This article showed that the structured early detection of asymptomatic liver cirrhosis (SEAL) approach, involving assessment of elevated liver enzymes and calculation of the aspartate aminotransferase (AST)-to-platelet ratio index (APRI), has the potential to increase the detection of advanced liver fibrosis and cirrhosis in the general population. This prospective study is important and timely for guiding the detection of early cirrhosis in clinical practice. After careful consideration, we put forward the following suggestions.

      Keywords

      Linked Article

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Labenz C.
        • Arslanow A.
        • Nguyen-Tat M.
        • Nagel M.
        • Worns M.A.
        • Reichert M.C.
        • et al.
        Structured early detection of asymptomatic liver cirrhosis: results of the population-based liver screening program SEAL.
        J Hepatol. 2022; (S0168-8278(22)00244-00246. https://dx.doi.org/10.1016/j.jhep.2022.04.009)
        View in Article
        • Wang W.
        • Zhao X.
        • Li G.
        • Wang L.
        • Chen Y.
        • Ma K.
        • et al.
        Diagnostic thresholds and performance of noninvasive fibrosis scores are limited by age in patients with chronic hepatitis B.
        J Med Virol. 2019; 91: 1279-1287
        View in Article
        • McPherson S.
        • Hardy T.
        • Dufour J.F.
        • Petta S.
        • Romero-Gomez M.
        • Allison M.
        • et al.
        Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis.
        Am J Gastroenterol. 2017; 112: 740-751
        View in Article
        • Bertot L.C.
        • Jeffrey G.P.
        • de Boer B.
        • MacQuillan G.
        • Garas G.
        • Chin J.
        • et al.
        Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
        Liver Int: official J Int Assoc Study Liver. 2018; 38: 1793-1802
        View in Article
        • Boursier J.
        • Canivet C.M.
        • Costentin C.
        • Lannes A.
        • Delamarre A.
        • Sturm N.
        • et al.
        Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications.
        Clin Gastroenterol Hepatol. 2022; (S1542-3565(22)00248-8. https://dx.doi.org/10.1016/j.cgh.2022.02.059)
        View in Article
        • Xiao G.
        • Yang J.
        • Yan L.
        Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis.
        Hepatology (Baltimore, Md). 2015; 61: 292-302
        View in Article
        • Harris R.
        • Harman D.J.
        • Card T.R.
        • Aithal G.P.
        • Guha I.N.
        Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.
        Lancet Gastroenterol Hepatol. 2017; 2: 288-297
        View in Article

      Article info

      Publication history

      Published online: July 14, 2022
      Accepted: June 24, 2022
      Received in revised form: June 23, 2022
      Received: May 29, 2022

      Footnotes

      Author names in bold designate shared co-first authorship.

      Identification

      DOI: https://doi.org/10.1016/j.jhep.2022.06.035

      Copyright

      © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX